<DOC>
	<DOCNO>NCT00043745</DOCNO>
	<brief_summary>This study provide valuable data whether soy isoflavones impact bone loss postmenopausal woman . The study help clarify potential mechanism contribute understand isoflavones alternative traditional hormone therapy .</brief_summary>
	<brief_title>Bone Response Soy Isoflavones Women</brief_title>
	<detailed_description>Soy protein , rich isoflavones ( estrogen-like compound ) , show prevent bone loss ovariectomized rat . Short-term preliminary study result perimenopausal woman suggest bone-sparing effect . Great interest isoflavones alternative hormone replacement therapy emerge , yet long-term efficacy isoflavones bone human unknown . Our objective determine three-year efficacy isoflavone-rich soy extract attenuate bone loss postmenopausal woman . The central hypothesis soy isoflavones attenuate bone loss woman maintain bone formation , modulate growth factor isoflavone metabolism . The rationale research current hormone therapy fraught adverse side effect , result non-compliance . This randomized , double-blind , placebo-controlled clinical trial examine effect two dos ( 80 120 mg daily ) isoflavone-rich soy extract bone non-osteoporotic postmenopausal woman ( N=234 ) . The specific aim study : 1 ) determine bone-preserving effect isoflavones lumbar spine bone mineral density ( BMD ) ; 2 ) relate treatment-induced change BMD change biochemical marker bone turnover ; 3 ) identify potential mechanism isoflavones prevent modulate bone loss measure endogenous estrogen , sex hormone-binding globulin , insulin-like growth factor-I ( IGF-I ) , urinary mineral , serum 25 ( OH ) vitamin D , plasma isoflavones metabolite , customary intake isoflavone-containing soy ; , 4 ) ascertain safety isoflavone-rich soy extract . Postmenopausal woman recruit two site ( 117 Iowa , 117 California ) . Random effect repeat measure analysis use characterize change BMD primary outcome , estimate treatment-induced effect , depict change marker bone turnover relation BMD change . We use intent-to-treat primary test , also account potential modulators ( reproductive hormone , IGF-I , plasma isoflavones ) affect bone , indicate specific aim 3 .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Early postmenopausal ( i.e. , menses past 12 month ) woman , upper limit 10 year since last cycle Natural menopause ( i.e. , hysterectomy oophorectomy ) Body mass index ( BMI ) &gt; 20 &lt; 30 Current previous ( within 12 month ) use hormone replacement therapy , hormonal contraceptive , estrogen , progestogen Current use pharmacologic agent , selective estrogenreceptor modulators ( SERMs ) ( e.g. , raloxifene tamoxifen ) antiresorptive agent ( e.g. , alendronate calcitonin ) , herbal therapy may estrogenic effect ( e.g. , herbimycin , tryphostins ) , cigarettes Strict vegan ( include lactoovo , lacto , ovovegetarians ) Metabolic bone disease , renal disease , history urolithiasis , cancer , cardiovascular disease , diabetes mellitus , respiratory disease , gastrointestinal disease , liver disease , chronic disease Firstdegree relative breast cancer Lumbar spine BMD &gt; = 1.5 standard deviation ( SD ) mean ( highrisk osteoporosis ) BMD &gt; = +1.0 SD mean</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>soy</keyword>
	<keyword>isoflavones</keyword>
	<keyword>alternative hormone therapy</keyword>
	<keyword>bone loss</keyword>
</DOC>